Mereo Biopharma Group Plc Net Income per Employee (MREO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Mereo Biopharma Group Plc  (NASDAQ: MREO)
 

Mereo Biopharma Group Plc Net Income per Employee

MREO's Quarterly Results, Trends, Rankings, Statistics
Mereo Biopharma Group Plc recorded a cumulative net loss of $-36 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 133 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 2637, from total ranking in previous quarter at 3164.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MREO Net Income per Employee (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -915,641 -1,073,795 -1,065,974 -1,270,513 -1,209,974
MREO's Total Ranking # 2637 # 3164 # 3308 # 3426 # 3268
Seq. Net Income Change - - - - -

MREO Company Profile >> Back to MREO Efficiency Comparisons >> Compare MREO Net Income per Employee to its Competitors

MREO Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 381
Overall Market # 2637

Net Income per Employee Statistics
High Average Low
$ 326,282 $ -1,345,378 $ -4,195,590
(Dec 31 2021)   (Dec 31 2020)




  News about Mereo Biopharma Group Plc Income per employee

Mereo BioPharma Raises $50 Million in Underwritten Offering, Focusing on Rare Diseases



London-based clinical-stage biopharmaceutical company, Mereo BioPharma Group plc, has recently disclosed the pricing of its underwritten offering of 12,531,300 American Depositary Shares (ADSs). Priced at $3.99 per ADS, the offering is expected to generate approximately $50.0 million in gross proceeds. Mereo plans to utilize these funds primarily for the advancement of its setrusumab program, covering pre-launch activities in Europe, supply, and other corporate purposes. This update comes in the backdrop of Mereo BioPharma Group s cumulative net loss of $34 million throughout the entire fiscal year ending in Q4 2022.

Mereo BioPharma Group s Underwritten Offering:
Mereo BioPharma Group plc recently announced the successful pricing of its underwritten offering, comprising 12,531,300 American Depositary Shares (ADSs). Each ADS is set at $3.99, and the offering is being executed as an underwritten registered direct offering under Nasdaq rules. This at-the-market offering strategy eliminates the need for a traditional public offering, allowing the company to conveniently raise capital.




Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-07-07T12:18:12+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.